Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Phizackerley

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
BMJ (Clinical Research Ed.)|December 16, 2014
Licensed indication for risperidone in dementiaDavid Phizackerley
Drug and Therapeutics Bulletin|November 28, 2024
PILs: all harms and no benefitsDavid Phizackerley
BMJ (Clinical Research Ed.)|July 25, 2013
Time to stop using minocycline?David Phizackerley
Drug and Therapeutics Bulletin|January 5, 2023
Swapping patients to edoxaban but at what cost?David Phizackerley
Drug and Therapeutics Bulletin|July 21, 2021
Aducanumab for Alzheimer's disease - too many unanswered questionsDavid Phizackerley
Drug and Therapeutics Bulletin|August 3, 2019
Social prescribing: right idea, wrong name?David Phizackerley
Drug and Therapeutics Bulletin|October 13, 2025
Medicines, but at what cost?David Phizackerley
Drug and Therapeutics Bulletin|March 3, 2019
A new DiRECTion for diabetesJames Cave, David Phizackerley
Drug and Therapeutics Bulletin|January 27, 2025
Prioritising shared decision-makingMichael Wilcock, David Phizackerley
Drug and Therapeutics Bulletin|December 11, 2021
Molnupiravir: evidence by press releaseJames A Cave, David Phizackerley
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
BMJ (Clinical Research Ed.)|December 16, 2014
Licensed indication for risperidone in dementiaDavid Phizackerley
Drug and Therapeutics Bulletin|November 28, 2024
PILs: all harms and no benefitsDavid Phizackerley
BMJ (Clinical Research Ed.)|July 25, 2013
Time to stop using minocycline?David Phizackerley
Drug and Therapeutics Bulletin|January 5, 2023
Swapping patients to edoxaban but at what cost?David Phizackerley
Drug and Therapeutics Bulletin|July 21, 2021
Aducanumab for Alzheimer's disease - too many unanswered questionsDavid Phizackerley
Drug and Therapeutics Bulletin|August 3, 2019
Social prescribing: right idea, wrong name?David Phizackerley
Drug and Therapeutics Bulletin|October 13, 2025
Medicines, but at what cost?David Phizackerley
Drug and Therapeutics Bulletin|March 3, 2019
A new DiRECTion for diabetesJames Cave, David Phizackerley
Drug and Therapeutics Bulletin|January 27, 2025
Prioritising shared decision-makingMichael Wilcock, David Phizackerley
Drug and Therapeutics Bulletin|December 11, 2021
Molnupiravir: evidence by press releaseJames A Cave, David Phizackerley
Pageof 4